FDA Approves New Engineered Viral Immunotherapy for Patients with Treatment-Resistant ...

The FDA has granted accelerated approval to Tudriqev, a genetically modified oncolytic viral therapy combined with nivolumab to treat adult patients with unresectable advanced melanoma who are refractory to anti-PD-1 therapy. Clinical trial data showed a 24% response rate with responses lasting a median of nearly 14 months in this difficult-to-treat population.

This Wire brief sits within Fusion42's coverage of Biotech. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.